

ASX ANNOUNCEMENT**Recruitment to close for important Alzheimer's trial - XanADu**

- Major milestone achieved in XanADu trial, with recruitment of patients closing on 26th October 2018
- XanADu study has generated high engagement from study sites and research teams with the potential for greater enrolment than the planned 174 patients
- Currently 169 patients have been enrolled in XanADu
- Early notice of recruitment closure allows adequate time for the final few prospective trial patients to be included in the study
- Final XanADu enrolment numbers to be announced over coming weeks

Sydney 22 October 2018. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to announce that recruitment of patients into XanADu, the Phase II clinical trial of Xanamem in the treatment of Alzheimer's disease, will cease on 26th October 2018.

Following this early notice of recruitment closure, the final few prospective patients should have adequate time to be included in the study. As with all trial participants, the patients will undergo a detailed eligibility evaluation before being enrolled into XanADu. Final patient enrolment numbers will be announced over the coming weeks, however over-enrolment above the planned 174 patients, is likely. Currently 169 patients have been enrolled into XanADu

The high recruitment rate of patients into XanADu follows high engagement from study sites and research teams participating in this important global Alzheimer's trial.

CEO of Actinogen Medical, Dr Bill Ketelbey commented: "We are delighted to have reached this important milestone in our XanADu trial with closure of recruitment."

"The eagerness and enthusiasm of patients and study site investigators to be involved in the XanADu trial is very pleasing. With over 50 million people suffering from this terrible disease globally, the need to discover additional drugs to treat Alzheimer's has never been more urgent, and we hope that the results from our trial represent an important next step in providing an effective new therapy to patients. We look forward to updating the market on our next key milestone of the final patient being enrolled into XanADu, as well as announcing the results for XanADu and some of the additional Xanamem studies, in Q2 2019".

ENDS**Actinogen Medical**

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor and Media Enquiries

Ben Walsh
WE Buchan
M: +61 411 520 012
E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, is enrolling 174 patients at 25 research sites across Australia, the UK and the USA. Enrolment is expected to complete in Q4 2018, with top-line results expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.